Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FABP7 | O15540 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028686 | 0.90 | ALDH1A1 (0.40) | ALDH1A1LGALS8FABP7FABP5TSHR | |
| SCHEMBL24603586 | 0.90 | ALDH1A1 (0.40) | ALDH1A1LGALS8FABP7FABP5TSHR | |
| SCHEMBL22689120 | 0.83 | TSHR (0.32) | TSHR | |
| SCHEMBL10309796 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LGALS8FABP7FABP5TSHR | |
| SCHEMBL29551166 | 0.79 | CA12 (0.36) | — | |
| SCHEMBL2580404 | 0.78 | NT5E (0.54) | NT5E | |
| SCHEMBL22778376 | 0.76 | NT5E (0.39) | LGALS8NT5E | |
| SCHEMBL19018767 | 0.76 | NT5E (0.39) | LGALS8NT5E | |
| SCHEMBL28656205 | 0.76 | ALDH1A1 (0.35) | ALDH1A1LGALS8FABP7FABP5TSHR | |
| SCHEMBL22108020 | 0.75 | LGALS8 (0.45) | ALDH1A1LGALS8MAPTFABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384765-B2 | Catecholamine prodrugs for use in the treatment of Parkinson's Disease | H. LUNDBECK A/S (DK) | 2025-08-12 | — | — | US | disclosed |
| US-20220213071-A1 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| EP-3972970-A1 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | H. Lundbeck A/S (DK) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020234274-A1 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | H. LUNDBECK A/S (DK) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213071-A1 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | COMT, SLC6A2, MAOB | ALDH1A1 336/4885LGALS8 4626/4885MAPT 188/4885 |
| US-12384765-B2 | Catecholamine prodrugs for use in the treatment of Parkinson's Disease | COMT, SLC6A2, MAOB | ALDH1A1 252/4885LGALS8 4676/4885MAPT 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.